SPRY insider buying and SEC filings, explained
ARS Pharmaceuticals, Inc. · CIK 1671858
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.5M
Planned sales (10b5-1)
$284K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 12, 2026 | Planned (10b5-1) | Eric Karas (Chief Commercial Officer) sold 25,000 shares at $10.00 ($250K), marked as a 10b5-1 plan trade. Holdings down 67% to 12,176 shares. | SEC filing Filed Jun 12, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Alexander A Fitzpatrick (Chief Legal Officer) sold 3,355 shares at $10.00 ($34K), marked as a 10b5-1 plan trade. Holdings down 4% to 90,910 shares. | SEC filing Filed Jun 12, 2026 |
| Nov 12, 2025 | Sale | Justin Chakma (Chief Business Officer) sold 166,380 shares at about $8.87 ($1.5M). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
24 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SPRY in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.